Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
L. Chu
Observed names:
Chu, L.,
Lisa Chu
Institutions:
University of Tasmania,
Launceston General Hospital,
LMC Diabetes & Endocrinology (Canada)
Observed institutions:
University of Tasmania,
Launceston General Hospital,
LMC Diabetes & Endocrinology (Canada)
ORCID:
0000-0002-6718-7792
Observed ORCID:
0000-0002-6718-7792
OpenAlex ID:
A5111324062
What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives
2025
·
A. Abitbol
, L. Chu
·
Diabetes Obesity and Metabolism
·
5
PDF
Effect of switching from intermittently scanned to real‐time continuous glucose monitoring on glycaemic outcomes in adults with type 1 diabetes: A real‐world, Canadian retrospective study
2025
·
Lisa Chu
, Alexander Abitbol
·
Diabetic Medicine
·
1
PDF
MACE With GLP-1RAs in Patients With Type 2 Diabetes—A Systematic Review and Meta-Analysis of Randomised Controlled Trials
2025
·
Y. Bao
, R. Ringrose
, et al.
·
Heart Lung and Circulation
Author response for "What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives"
2025
·
A. Abitbol
, L. Chu
·
Publons reviews and discussion
The 9th Annual Biosimilar Asia 2018 (May 16-17, 2018 - Shanghai, China)
2018
·
Chu, L.
·
Drugs of today
Show more works
View as search
Works count:
5
Citation count:
6
H-index:
1
I10-index:
Year
Topic
Type